Cargando…
An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076583/ https://www.ncbi.nlm.nih.gov/pubmed/35533972 http://dx.doi.org/10.1016/j.cmi.2022.04.016 |
| _version_ | 1784701957598871552 |
|---|---|
| author | Ader, Florence |
| author_facet | Ader, Florence |
| author_sort | Ader, Florence |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9076583 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90765832022-05-09 An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results Ader, Florence Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-09 2022-05-07 /pmc/articles/PMC9076583/ /pubmed/35533972 http://dx.doi.org/10.1016/j.cmi.2022.04.016 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Ader, Florence An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title | An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title_full | An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title_fullStr | An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title_full_unstemmed | An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title_short | An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results |
| title_sort | open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with covid-19: final results |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076583/ https://www.ncbi.nlm.nih.gov/pubmed/35533972 http://dx.doi.org/10.1016/j.cmi.2022.04.016 |
| work_keys_str_mv | AT aderflorence anopenlabelrandomizedcontrolledtrialoftheeffectoflopinavirandritonavirlopinavirandritonavirplusinterferonb1aandhydroxychloroquineinhospitalizedpatientswithcovid19finalresults AT anopenlabelrandomizedcontrolledtrialoftheeffectoflopinavirandritonavirlopinavirandritonavirplusinterferonb1aandhydroxychloroquineinhospitalizedpatientswithcovid19finalresults AT aderflorence openlabelrandomizedcontrolledtrialoftheeffectoflopinavirandritonavirlopinavirandritonavirplusinterferonb1aandhydroxychloroquineinhospitalizedpatientswithcovid19finalresults AT openlabelrandomizedcontrolledtrialoftheeffectoflopinavirandritonavirlopinavirandritonavirplusinterferonb1aandhydroxychloroquineinhospitalizedpatientswithcovid19finalresults |